Best of SABCS® - East

Regional Director
Joseph A. Sparano, MD, FACP
OncologyDeputy Director of The Tisch Cancer InstituteMount Sinai Health SystemNew York, New York
Program Goals & Content Overview
As new clinical data continues to emerge as a result of ongoing research in breast cancer diagnostics and therapeutics, official Best of SABCS® programs cover these important developments in each of the live, regional events. Each regional event provides an educational forum for local researchers and clinicians to discuss the most pertinent basic, translational, and clinical breast cancer research presented at the annual SABCS® meeting.
Topics and discussions for each Best of SABCS® program are drawn from key presentations at SABCS® 2023, focusing on results of breast cancer research that helps clinicians understand current trends and forthcoming treatments that will optimize patient care outcomes. Significantly important content from SABCS® includes new drug therapy approvals and clinical trial results, updates in breast cancer screening and diagnostics, and best practices to be implemented in clinical care of patients.
The goals of the Best of SABCS® programs are to review and critically assess practice-changing results of emerging breast cancer research, propose best practices for implementing diagnostic and therapeutic strategies, and close knowledge and clinical practice gaps in the management of patients with breast cancer.
Date & Time
January 13, 2024 8:30 am - 2:20 pm
Location
CONVENE (aka ETC.venues) - located at 360 Madison Ave., New York City NY 10017
Program Fee
Physician
$50
Nurse/Nurse Practitioner/Physician Assistant
$25
Resident/Fellow
$25
NY Metropolitan Breast Cancer Group Member
$35
Industry
$125
2023 Preliminary Agenda
7:30 - 8:30 AM
Registration - Continental Breakfast

8:30 - 8:40 AM
Welcome, Program Overview and Pre-Test

Joseph Sparano, MD, FACP – Chief of Hematology and Medical Oncology, Deputy Director, The Tisch Cancer Institute, Mount Sinai Health System

8:40 - 9:25 AM
ER Positive Breast Cancer

Neil Iyengar, MD, Associate Attending Physician,Memorial Sloan Kettering Cancer Center

9:25 - 10:05 AM
HER2-Positive and Triple Negative Breast Cancer

Kate Lathrop, MD, Assistant Professor, Dept. of Medicine, Division of Hematology and Oncology, University of Texas Health Science Center at San Antonio, Director of Education, SABCS

10:05 - 10:20 AM
Clinical Case Studies and Panel Q and A

10:20 - 10:35 AM
Break and visit with Exhibitors

10:35 - 11:10 AM
Local Therapy

Elizabeth Mittendorf, MD, PhD, MHCM, Professor of Surgery Harvard Medical School, Rob and Karen Hale Distinguished Chair in Surgical Oncology, Brigham and Women’s Hospital

11:10 -11:55 AM
Prevention, Survivorship and Health Disparities

Dawn Hershman, MD, MS, FASCO, American Cancer Society Professor of Medicine and Epidemiology, Director of Breast Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center

11:55 -12:15 AM
Lunch Break

12:15 -1:00 PM
Supported Symposium

1:05 -1:40 PM
Translational Science

Joseph Sparano, MD, FACP, Chief of Hematology and Medical Oncology, Deputy Director, The Tisch Cancer Institute, Mount Sinai Health System

1:40 - 1:55 PM
Panel Q and A

1:55 -2:00 PM
Closing Remarks and Post Test

Accreditation Statement

The UT Health Science Center San Antonio is accredited by the ACCME (Accreditation Council for Continuing Medical Education) to provide continuing medical education for physicians.

The UT Health Science Center San Antonio has approved this program for AMA PRA Category 1 Credits™.

Target Audience
These regional Best of SABCS programs are directed to academic and community physicians, medical residents and fellows training in oncology subspecialties, physician assistants, nurse practitioners and basic/translational researchers involved in breast cancer. Specialties include medical, surgical, gynecologic, and radiation oncology, as well as other pertinent healthcare professionals involved in breast cancer medicine.
These programs are supported by educational grants from
Astra Zeneca
Daiichi Sankyo
Gilead
Hologic
Merck
Novartis
Pfizer
SeaGen
Puma Biotechnology